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tal for Sick Children, reviews 70 charts representing healthy chil-
dren who had strabismus surgery and were given ondansetron
or dimenhydrinate prophylactically. Cost-consequence analysis 
is used to compare costs and outcomes. Cost information was
obtained from the ﬁnance department and the hospital phar-
macy. Cost items include the acquisition cost of the antiemetics,
the cost of administering the agents, the cost length of stay in
the post anesthetic care unit (PACU) and the cost of an episode
of emesis, including laundry expense, materials, nursing time,
housekeeping time and rescue treatment. The outcome measure
used to determine the effectiveness of the antiemetics is the
number of POV-free patients. This represents patients that did
not experience POV that would have otherwise done so without
the prophylactic administration of an antiemetic. RESULTS: In
an adjusted cohort of 100, the number of POV-free patients 
was 45.3 for ondansetron and 38.2 for dimenhydrinate. The
costs per patient were CAD$185.34 for ondansetron and
CAD$232.34 for dimenhydrinate. The length of stay in the
PACU represented over 97% of total costs, and the mean lengths
of stay in the PACU for ondansetron and dimenhydrinate were
signiﬁcantly different, 3.43 and 4.41 hours, respectively. CON-
CLUSION: Ondansetron is more effective in reducing POV and
less expensive than dimenhydrinate. However, the dominance
ondansetron offers over dimenhydrinate is dependent on the
length of stay in the PACU. This study should serve as a pilot
for a larger scale investigation on the correlation between the
length of stay in the PACU and the antiemetic agent used.
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OBJECTIVE: To assess trends in UK GP consultations and pre-
scribing according to BMI classiﬁcation. METHODS: The 
DIN-LINK longitudinal patient database comprises 1.5 million
anonymised medical records from GP practices across Great
Britain. This analysis was based on a cohort of 75,738 DIN-
LINK patients, with BMI status recorded, who had seen their GP
in the year ending August 2004. Patients were grouped accord-
ing to three BMI classiﬁcations: normal (BMI < 25), overweight
(25–30) and obese (>30). We examined the mean number of con-
sultations per patient and the lengths of these consultations in
the three groups. The number and type of prescriptions issued
were also measured. RESULTS: The mean number of consulta-
tions per patient increased as patients’ BMI increased from
normal to obese. Patients with a BMI below 25 saw their GP a
mean 6.4 times [SD 36.5] during the year; this was signiﬁcantly
lower than patients who were overweight (7.5 [35.5]). Patients
classiﬁed as obese had the highest mean number of consultations
at 8.7 [35.3]. This trend was repeated when the number of pre-
scriptions issued per consultation was investigated. In the normal
BMI group a mean 0.87 prescriptions were issued per consulta-
tion, increasing to 0.99 for the overweight individuals; this rose
again to 1.17 in the obese group. Over the course of the year,
obese patients were issued with a mean 10.3 prescriptions,
almost twice as many as normal BMI patients (mean 5.6). There
appeared to be only slight increases in the lengths of consulta-
tions as BMI classiﬁcation increased from normal to obese.
CONCLUSION: Our preliminary analysis shows that patients
with a higher BMI are likely to visit their GP more frequently,
and be issued with more prescriptions, than those of normal
weight. The length of a consultation, however, does not appear
to be inﬂuenced greatly by BMI status.
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OBJECTIVES: In patients with type-1 diabetes, poor glycemic
control is associated with increased risk of complications. A
recent clinical study provided evidence that basal/bolus treat-
ment with insulin detemir+insulin aspart (IDet/IAsp) improved
HbA1c (0.22%-points lower after 18 weeks), reduced risk of
hypoglycemic events (by 21%), and decreased body mass index
(BMI) (-0.3kg .m-2) in comparison to neutral protamine Hage-
dorn insulin+human soluble insulin (NPH/HSI). The aim of this
study was to evaluate the long-term impact of these short-term
clinical beneﬁts in patients with type-1 diabetes in the Dutch
setting. METHODS: We used a validated computer simulation
model (CORE Diabetes Model) to project long-term clinical and
cost outcomes in patients receiving IDet/IAsp or NPH/HSI based
on the clinical study ﬁndings. Standard Markov sub-models were
combined to simulation the incidence and progression of com-
plications (cardiovascular disease, neuropathy, renal and eye
disease). Transition probabilities and HbA1c-dependent adjust-
ments were derived from published sources. Baseline cohort
characteristics and treatment effect data were based on the clin-
ical study. Direct costs were retrieved from published sources and
projected over patient lifetimes from a Dutch National Health
Care perspective. Costs and clinical beneﬁts were discounted 
at 4% per annum. RESULTS: IDet/IAsp treatment was associ-
ated with fewer diabetes-related complications, improved life
expectancy (0.15 life years gained) and quality-adjusted life
expectancy (0.10 QALYs gained) compared to NPH/HSI. Mean
total lifetime costs were 872€ per patient higher with IDet/IAsp,
leading to incremental cost-effectiveness ratios (ICERs) of 5813€
per life year and 8720€ per QALY gained. CONCLUSION:
Short-term clinical beneﬁts in glycemic control, hypoglycemic
event rates and BMI associated with IDet/IAsp basal/bolus
therapy were projected to lead to fewer complications, and
improved life expectancy and quality-adjusted life expectancy
over patient lifetimes compared to NPH/HSI. This resulted in
ICERs for IDet/IAsp versus NPH/HSI in the range considered to
represent excellent value for money.
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OBJECTIVES: Obesity adjustments may have a substantial
effect on models of long-term cost-effectiveness of intensive
lifestyle intervention to prevent type -2 diabetes (T2DM). The
objectives of this study were to: 1) design a long-term cost-
effectiveness model to evaluate the use of lifestyle intervention
to prevent progression from impaired glucose tolerance (IGT) to
T2DM; and 2) to analyze the effect of obesity adjustments for
mortality and costs on the model. METHODS: Markov models
were developed based on the DPP results incorporating the states
of normal glucose tolerance (NGT), IGT, T2DM and death.
Transition probabilities were derived from DPP and current lit-
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erature. A three-year intervention was assumed with outcomes
of: 1) a -year duration of effect; and 2) a lifetime duration of
effect. A second set of models included an additional increased
cost of illness for obese NGT subjects, and an increased mortal-
ity rate for obese T2DM subjects over the base-case. RESULTS:
Lifestyle dominated placebo in all models tested. In the obesity-
adjusted model, subjects had higher lifetime costs and shorter
duration of life. The following incremental cost-effectiveness
ratios were derived: 1) base-case model - three-year duration 
= -$16,064/LY; 2) base-case model - lifetime duration =
-$19,496; 3) obesity-adjusted model - three-year duration =
-$2278/LY; and 4) obesity-adjusted model - lifetime duration 
= -$4281/LY. A maximal acceptable cost of intervention per year
for the three-year duration of effect that could be used to main-
tain lifestyle dominance was also established. The value for the
obesity-adjusted model was approximately 45% of that found
for the base-case model. CONCLUSION: Researchers examin-
ing the cost-effectiveness of intensive lifestyle intervention to
prevent T2DM should be aware of the potential effect of obesity
adjustments when developing models, in particular, the effects of
obesity on mortality and costs for NGT subjects.
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OBJECTIVE: Cost models are often criticized for limited or
obscure selection of transition probabilities, especially when
several estimates are available. We conducted a systematic review
of population-based studies estimating the impact of improved
glycemic control on the incidence of microvascular (retinopathy,
nephropathy, and neuropathy/diabetic sores and ulcers/lower
extremity amputations(LEA)) and macrovascular (myocardial
infarction and stroke) complications of type-2 diabetes mellitus.
METHODS: Literature searches using keyword and MESH algo-
rithms in the PubMed bibliographic database, and hand search.
Studies had to be published between 1985–2004, conducted in
Australia, North America, or Europe, and compare the risk for
macrovascular or microvascular complications per % difference
in HbA1c over three to ten years. Two reviewers independently
extracted study and population characteristics and the relative
risk (RR) associated with a 1% crude difference in HbA1c.
Odds-ratios were treated as RRs. Meta-analytic pooled estimates
were calculated for complications with more than one RR esti-
mate using random effects models. To account for variation in
study design validity cohort and experimental studies were
weighted twice as much as cross-sectional studies. RESULTS:
RR estimates were obtained for retinopathy (eight estimates),
nephropathy (four), all-cause mortality (two), myocardial infarc-
tion (one), diabetic sores and ulcers (one), and LEA (one). No
RR estimate was identiﬁed for stroke. A crude 1% difference in
HbA1c was found to reduce the likelihood of retinopathy by
25% (95% CI: 19%–30%), nephropathy by 22% (13%–32%),
all-cause mortality by 17% (10%–27%), myocardial infarction
by 16% (9%–27%), diabetic sores and ulcers by 30%
(20%–50%), and LEA by 30% (10%–50%). CONCLUSIONS:
A crude 1% decrease in HbA1c leads to a signiﬁcant reduction
in the incidence of serious diabetic complications. Epidemiologic
studies were surprisingly scarce, especially for macrovascular
complications and population subgroups. Laboratory-enriched
claims databases would be ideal for future studies relating
HbA1c to diabetic complications.
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OBJECTIVES: To estimate the treatment costs incurred by
Alzheimer’s disease (AD) patients in Medi-Cal over an eight-year
span (1995–2002). METHODS: AD patients were identiﬁed
(ICD-9 = 331.0) using 20% sample of Medi-Cal administrative
claims data from January 1, 1995 to December 31, 2002, and
were 1 :10 matched to the a control group without AD diagno-
sis based on age and gender. Annual total treatment costs were
calculated for both groups. For patients with AD, yearly expen-
ditures after the initial diagnosis were also measured. All costs
were eligibility-adjusted by the number of eligible months.
RESULTS: In total, 6494 cases and 64,940 controls were iden-
tiﬁed. The average age was 83.6 (+/-12.2) and 69.5% were
female. The average annual treatment costs were more than two-
fold higher for AD patients than controls ($13,978 vs. $6188, 
p < 0.0001). Without adjusting for inﬂation, the treatment costs
for a typical AD patient increased from $10,032 in 1995 to
$19,446 in 2002. During the ﬁrst year after the initial diagno-
sis, the average treatment costs for AD was $17,725. The costs
increased slightly over time for those patients who survived and
remained in Medi-Cal and by the fourth year, the treatment costs
increased to $18,064. For the ﬁrst year, nursing home costs
accounted 81% of the total costs, followed by pharmacy (8%)
then outpatient (6%). For AD alone, it is estimated that Medi-
Cal paid an incremental $84 million in 1995 and $200 million
in 2002. CONCLUSIONS: This study demonstrated that AD is
an increasingly costly disease, and treatment costs were doubled
from 1995–2002. Consistent with previous studies, nursing
home care was the major component of health care costs.
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OBJECTIVES: To assess the one-year direct mental health costs
of treating crisis-prone schizophrenia patients. METHODS:
Data were drawn from a large multi-site prospective naturalistic
study of schizophrenia patients in the United States, conducted
between July, 1997 and September, 2003. Participants were
treated at large mental health systems, including the Veterans
Health Administration, community health centers, community
and state hospitals, and university health care delivery systems.
Total mental health cost and component costs (psychiatric 
hospitalizations, antipsychotic medications, other psychotropic
medications, day treatment, emergency psychiatric services, psy-
chosocial/rehabilitation group therapy, individual therapy, med-
ication management, and case management), were calculated for
1557 participants with complete medical information. Propen-
sity score adjusted bootstrap re-sampling methods were used to
compare one-year direct costs of ﬁve crisis-prone subgroups,
deﬁned as having: prior suicide attempt (in past four weeks,
yes/no), psychiatric hospitalization (in past six months, yes/no),
prior arrest (in past six months, yes/no), prior violent behaviors
